Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: TRIIBoy who wrote (2185)	7/15/1999 1:43:00 PM
From: out_of_the_loop	Read Replies (3) \| Respond to of 10293

What is hilarious is that you have no idea who and what you are dealing with and talking about. 1. Just because they made an announcement today does not mean the 2nd clinicals started today. Geez. 2. The duration of a clinical trial depends on how much a dose has to be tweaked (not being tested in this case) and the duration of the disease process being studied (in this case 0-14 days) until measurable clinical endpoints/data points can be recorded. The duration also depends on getting enough patients so indirectly depends on the prevalence of the disease. One of the reasons these infections are called the "common cold" is because they are just that. Now, what part of the announcement is hilarious besides the above explanation to your flippant error? Was it the WalMart, etc? Was it the two major Universities? Was it that they mentioned that it might have use outside the common cold? And where did you short it?

To: TRIIBoy who wrote (2185)	7/15/1999 2:26:00 PM
From: BDR	Respond to of 10293

< GUMM news is hilarious> It would be nice to see published data instead of press releases. For the record the Zicam article is not is this week's NEJM. I am sure, if it gets published, that we will hear about it from the company. However, I doubt the company will issue a release stating that it has been rejected. Given some of the delays that can occur in getting a paper reviewed, rewritten and ready for publication, it is hard to know when to expect to see the study.